Lomond Therapeutics, a subsidiary of Eilean Therapeutics LLC, today announced an abstract related to the company's Lomonitinib, a highly potent and selective pan-FLT3/IRAK4 inhibitor that targets ...

As questions surround the fate of Intel and its New Albany plant, some oversight groups are scrutinizing “forever chemicals” ...

To bridge the gap between diaper-changing stations available in men and women’s restrooms, the City of Columbus approved ...